Top Clean Energy Stocks To Buy For 2016

Top Clean Energy Stocks To Buy For 2016: Coronado Biosciences Inc (CNDO)

Coronado Biosciences, Inc., incorporated on June 28, 2006, is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. The Company's two principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201 (TSO) a biologic comprising of the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohn's disease (Crohn's), ulcerative colitis (UC) and multiple sclerosis (MS), and CNDO-109, a compound that activates natural killer (NK) cells of the immune system to seek and destroy cancer cells, for the treatment of acute myeloid leukemia (AML). In January 2011, the Company acquired the OvaMed GmbH License.

TSO

TSO is the microscopic eggs of a parasitic helminth, or worm, that is found in pigs. In September 2011, the Company filed an Investigational New Drug Application (IND) with t he United States Food and Drug Administration (FDA) and it initiated a single dose, dose escalation study in patients with Crohn's in February 2012. The Phase 1 clinical trial was a multi-center, sequential dose-escalation, double-blind, placebo-controlled study, the primary objective of which was to evaluate the safety and tolerability of TSO. The trial enrolled 36 patients with Crohn's ranging in age from 20 to 54 with an equal distribution of male and female patients in three single dose cohorts of orally administered 500, 2500 and 7500 ova. Each cohort had 12 patients, with nine patients receiving TSO and three receiving placebo.

CNDO-109

CNDO-109 is a lysate (disrupted CTV-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor NK cells. CTV-1 is a leukemic cell line recently re-class! ified as a T-cell acute lymphocytic leukemia (ALL). The Company has worldwide rights to develop and commercialize CNDO-109 activated NK cells for the treatment of cancer fro! m UCLB. In February 2012, the Company submitted an IND for the CNDO-109 activated NK cell product in the United States. The treatment of patients with CNDO-109 activated NK cells involves several steps. The activated NK cells are infused into the patient after resting NK cells are incubated with CNDO-109 for at least eight hours. Preparation of CNDO-109 activated NK cells takes about 24 hours from start to finish.

The Company competes with Centocor Ortho Biotech Inc.'s Remicade , UCB S.A.'s Cimzia, Abbott Laboratories' Humira, Biogen Idec's Avonex, Bayer Healthcare Pharmaceuticals' Betaseron, Teva Pharmaceuticals Industries, Ltd.'s Copaxone and Novartis AG's Gilenya.

Advisors' Opinion:

• [By Roberto Pedone]

  One under-$10 biopharmaceutical player that's quickly moving within range of triggering a major breakout trade is Coronado Biosciences (CNDO), which is focused on novel immunotherapy biologic agents for autoimmune diseases and cancer. This stock has been hit hard by the bears in 2013, with shares off by 43%.

  If you take a look at the chart for Coronado Biosciences, you'll notice that this stock has been uptrending strong since it double bottomed in November, with shares moving higher from its low of $1.25 to its intraday high of $2.58 a share. During that uptrend, shares of CNDO have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of CNDO within range of triggering a major breakout trade.

  Traders should now look for long-biased trades in CNDO if it manages to break out above some key overhead resistance at $2.70 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.97 million shares.! If that ! breakout hits soon, then CNDO will set up to re-fill some of its previous gap down zone from October that started near $7 a share. Some possible upside targets if CNDO gets into that gap with volume are $4 to $5 a share.

  Traders can look to buy CNDO off any weakness to anticipate that breakout and simply use a stop that sits right around some key near-term support at $2 a share. One can also buy CNDO off strength once it takes out $2.70 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Ben Fox Rubin]

  Biopharmaceutical firm Coronado Biosciences Inc.(CNDO) said a recent pilot study found that the first five patients using its potential autism treatment showed statistically significant separation from placebo, in favor of the drug. The treatment was also well-tolerated. The study is still ongoing. Shares jumped 26% to $2.25 premarket.

• [By James E. Brumley]

  The last few weeks haven't been particularly encouraging for Crohn's disease sufferers. In August, GlaxoSmithKline (NYSE: GSK) and ChemoCentryx (NASDAQ:CCXI) reported that a jointly-developed Crohn's drug, vercirnon, had failed to meet its late-stage trial endpoints. Though the in-development drug isn't dead in the water (GSK and CCXI could rework the drug, the testing regimen, or use it for other indications), it doesn't look good. Then this month - just a few days ago - Coronado Biosciences Inc. (NASDAQ:CNDO) reported that its Phase 3 trials of Crohn's disease drug TSO had also failed to meet its primary endpoints as well. Like vercirnon, CNDO isn't completely out of luck here with the treatment, but forging ahead with further development of the treatment is grasping at straws. Crohn's sufferers don't need to give up home just yet, however - TNI Biotech Inc. (OTCMKTS:TNIB) appears to have a Crohn's treatment that works, and should be able to sidestep the problems that pl agued ChemoCentryx, GlaxoSmithKline, and Coronado Biosciences.

  s! ource from Top Stocks For 2015:http://www.topstocksblog.com/top-clean-energy-stocks-to-buy-for-2016-2.html